Clinical Feautures APS/X
Jun 12, 2025, 09:14
Understanding Antiphospholipid Syndrome (APS): Diagnosis and Clinical Clues Every Clinician Should Know-by APS Foundation of America
The APS Foundation of America has pinned a critical update on their X page, shedding light on the diagnostic criteria and clinical features of Antiphospholipid Syndrome (APS)—a serious autoimmune condition that significantly increases the risk of blood clots, pregnancy complications, and organ damage.
Diagnosis of APS requires both clinical manifestations and positive laboratory findings. The most commonly used tests include:
Anticardiolipin antibodies (IgG, IgM, IgA)
Lupus anticoagulant testing (e.g., dRVVT, aPTT, mixing studies)
Anti-β2 glycoprotein I antibodies (IgG, IgM, IgA)
These tests help differentiate APS from other causes of coagulopathy and are essential for accurate classification and management.
Clinical features may include:
Recurrent venous or arterial thrombosis
Recurrent miscarriages or severe pregnancy complications (e.g., pre-eclampsia)
Thrombocytopenia
Stroke or transient ischemic attacks
Livedo reticularis, skin ulcers, and — in severe cases — Catastrophic APS
APS is a multisystemic disorder that requires high clinical suspicion, especially in young patients with unexplained thrombotic events or adverse pregnancy outcomes.
See full details and expert perspectives now on Hemostasis Today.
American Society of Hematology
Anticardiolipin Antibodies
Antiphospholipid Syndrome
APS Awareness
APS Diagnosis
APSFA
Autoimmune Coagulopathy
Catastrophic APS
Hematology
Hemostasis Today
International Society on Thrombosis and Haemostasis (ISTH)
Lupus Anticoagulant
Pregnancy Loss
Th APS Foundation of America
thrombosis
β2 Glycoprotein I
-
Aug 3, 2025, 04:27Thomas Reiser Invites You to ISTH’s Engaging Podcasts and YouTube Channel
-
Aug 3, 2025, 04:12Fresh Frozen Facts Part 4: A Thoughtful Look at Plasma Transfusion by Dr. Caitlin Raymond
-
Aug 2, 2025, 19:15WFH Workshop Highlights: Advancing ITI Success and FVIII Optimization in Hemophilia Care
-
Aug 2, 2025, 18:28Filippo Crea Shares Some AI-Insights on Recurrent STEMI
-
Aug 2, 2025, 18:05MSK Cancer Center CME: Expert Insights on Benign Hematology, Hemostasis and Thrombosis
-
Aug 3, 2025, 03:54Cedric Hermans on the Inspiring Impact of the WFH Humanitarian Aid Program Worldwide
-
Aug 2, 2025, 20:14Sebastian Szmit Shares Patients’ Perspectives on Decision‑Making for Antithrombotic Therapy in Advanced Cancer
-
Aug 2, 2025, 19:44Emmanuel J Favaloro Highlights New Publication Marking 100 Years of von Willebrand Disease
-
Aug 2, 2025, 18:53Acute Ischemic Minor Stroke and IV Thrombolysis: Findings from a Danish Nationwide Study
-
Aug 2, 2025, 04:31Acute VTE in Women: Continue Contraception, Select the Right Anticoagulant
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab
-
Jul 28, 2025, 12:53Zambia’s Hemophilia Prophylaxis Success
-
Jul 26, 2025, 16:14Cesar Garrido: Forging Strong Partnerships on WHA78 ''Global Health Equity'' Event
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders
Aug 3, 2025, 04:27
Aug 2, 2025, 18:28
Aug 2, 2025, 17:56